ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Radotinib, developed as a BCR/ABL tyrosine kinase inhibitor (TKI), is approved for the second-line treatment of chronic myeloid leukemia (CML) in South Korea.